Back to Search Start Over

Long-term follow-up of patients with tetralogy of fallot and implantable cardioverter defibrillator–The DAI-T4F nationwide registry

Authors :
Guillaume Duthoit
Mikael Laredo
Antoine Da Costa
Romain Eschalier
Fabien Labombarda
Laurent Fauchier
Benoit Guy-Moyat
Laurence Iserin
Pierre Winum
Marie-Cécile Perier
Philippe Maury
Nicolas Combes
Victor Waldmann
Didier Irles
Philippe Lagrange
Magalie Ladouceur
Jean-Benoit Thambo
Bertrand Pierre
Eloi Marijon
Jean-Marc Sellal
Grégoire Massoulié
Maxime De Guillebon
Ardalan Sharifzadehgan
Jacques Mansourati
Sandro Ninni
Penelope Pujadas
Linda Koutbi
Anouk Asselin
Pascal Sagnol
Nathalie Elbaz
Rodrigue Garcia
Dai-T F investigators
Caroline Audinet
G Clerici
Kumar Narayanan
Amel Mathiron
Xavier Jouven
Frédéric Anselme
Camille Walton
Anne Messali
Jean-Baptiste Gourraud
Yvette Bernard
Charles Guenancia
Alexis Hermida
Raphaël P. Martins
Pierre Bordachar
Cyril Zakine
Francis Bessière
Pierre Mondoly
Franck Halimi
Paul Bru
C. Marquie
François Jourda
Pascal Defaye
Frederic Sacher
Sok Sithikun Bun
Jean-Luc Pasquié
Cédric Nguyen
Abdeslam Bouzeman
Source :
Archives of Cardiovascular Diseases Supplements. 13:271-272
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Introduction Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, and sudden cardiac death represents an important mode of death in these patients. Data evaluating the implantable cardioverter defibrillator (ICD) in this patient population remain scarce. Objective We aimed to describe long-term follow-up of TOF patients implanted with ICD through a nationwide French registry. Methods Nationwide French Registry including all TOF patients with an ICD initiated in 2010 by the French Institute of Health and Medical Research. The primary time to event endpoint was the time from ICD implantation to first appropriate ICD therapy. Clinical events were centrally adjudicated by a blinded committee. Results A total of 165 patients (mean age 42.2 ± 13.3 years, 70.1% males) were included from 40 centers, including 104 (63.0%) in secondary prevention. During a median (IQR) follow-up of 6.8 (2.5–11.4) years, 78 (47.3%) patients received at least one appropriate ICD therapy. The annual incidence of the primary outcome was 10.5% (7.1% and 12.5% in primary and secondary prevention, respectively, P = 0.03). Overall, 71 (43.0%) patients presented with at least one ICD complication, including inappropriate shocks in 42 (25.5%) patients and lead dysfunction in 36 (21.8%) patients. Among 61 (37.0%) primary prevention patients, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patients with respectively no, one, two, or ≥ three guideline-recommended risk factors. QRS fragmentation was the only independent predictor of appropriate ICD therapies (HR 3.47, 95% CI 1.19–10.11), and its integration in a model with current criteria increased the 5-year time-dependent area under the curve from 0.68 to 0.81 (P = 0.006) ( Fig. 1 ). Conclusions Patients with TOF and an ICD experience high rates of appropriate therapies, including those implanted in primary prevention. The considerable long-term burden of ICD-related complications, however, underlines the need for careful candidate selection. A combination of easy-to-use criteria including QRS fragmentation might improve risk stratification.

Details

ISSN :
18786480
Volume :
13
Database :
OpenAIRE
Journal :
Archives of Cardiovascular Diseases Supplements
Accession number :
edsair.doi...........34c923ffd6808190ac3c5cf7763f2c42
Full Text :
https://doi.org/10.1016/j.acvdsp.2021.06.006